Triptolide induces cell-cycle arrest and apoptosis of human multiple myeloma cells in vitro via altering expression of histone demethylase LSD1 and JMJD2B
Tóm tắt
Từ khóa
Tài liệu tham khảo
Carter BZ, Mak DH, Schober WD, McQueen T, Harris D, Estrov Z, et al. Tliptolide induces caspase-dependent cell death mediated via the mitochondfial pathway in leukemic cells. Blood 2006; 108: 630–7.
Kiviharju TM, Lecane PS, Sellers RG, Peehl DM . Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. Clin Cancer Res 2002; 8: 2666–74.
Pigneux A, Mahon FX, Uhalde M, Jeanneteau M, Lacombe F, Milpied N, et al. Triptolide cooperates with chemotherapy to induce apoptosis in acute myeloid leukemia cells. Exp Hematol 2008; 36: 1648–59.
Yang SM, Chen JG, Guo Z, Xu XM, Wang LP, Pei XF, et al. Triptolide inhibits the growth and metastasis of solid tumors. Mol Cancer Ther 2003; 2: 65–72.
Zhang C, Cui GH, Liu F, Wu QL, Chen Y . Inhibitory effect of triptolide on lymph node metastasis in patients with non-Hodgkin lymphoma by regulating SDF-1/CXCR4 axis in vitro. Acta Pharmacol Sin 2006; 27: 1438–46.
Zhang C, Cui GH, Liu F, Wu QL, Chen Y . Effects of triptolide on cell proliferation and CXCR4 expression in Burkitt's lymphoma Raji cells in vitro. Chin J Cancer Res 2007; 19: 27–31.
Carter BZ, Mak DH, Schober WD, Dietrich MF, Pinilla C, VassileV LT, et al. Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. Blood 2008; 111: 3742–50.
Yang M, Huang J, Pan HZ, Jin J . Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3k/Akt/NF-kappa B pathways in human multiple myeloma cells. Int J Mol Med 2008; 22: 489–96.
Ng MHL, To KW, Lo KW, Chan S, Tsang KS, Cheng SH, et al. Frequent death-associated protein kinase promoter hypermethylation in multiple myeloma. Clin Cancer Res 2001; 7: 1724–9.
Galm O, Wilop S, Reichelt J, Jost E, Gehbauer G, Herman JG, et al. DNA methylation changes in multiple myeloma. Leukemia 2004; 18: 1687–92.
Chim CS, Pang R, Fung TK, Choi CL, Liang R . Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma. Leukemia 2007; 21: 2527–36.
Lohrum M, Stunnenberg HG, Logie C . The new frontier in cancer research: Deciphering cancer epigenetics. Int J Biochem Cell Biol 2007; 39: 1450–61.
Vakoc CR, Mandat SA, Olenschock BA, Blobel GA . Histone H3 lysine 9 methylation and HP1 gamma are associated with transcription elongation through mammalian chromatin. Blood 2005; 106: 1734.
Lim S, Metzger E, Schule R, Kirfel J, Buettner R . Epigenetic regulation of cancer growth by histone demethylases. Int J Cancer 2010; 127: 1991–8.
Zhao F, Chen Y, Li R, Liu Y, Wen L, Zhang C . Triptolide alters histone H3K9 and H3K27 methylation state and induces G0/G1 arrest and caspase-dependent apoptosis in multiple myeloma in vitro. Toxicology 2010; 267: 70–9.
Eissenberg JC, Shilatifard A . Histone H3 lysine 4 (H3K4) methylation in development and differentiation. Dev Biol 2010; 339: 240–49.
Zhao F, Chen Y, Zeng LL, Li R, Zeng R, Wen L, et al. Role of triptolide in cell proliferation, cell cycle arrest, apoptosis and histone methylation in multiple myeloma U266 cells. Eur J Pharmacology 2010; 646: 1–11.
Zhao F, Chen Y, Zeng LL, Li R, Zeng R, Wen L, et al. Effects of triptolide on RIZ1 expression, proliferation, and apoptosis in multiple myeloma U266 cells. Acta Pharmacol Sin 2010; 31: 733–40.
Strahl BD, Grant PA, Briggs SD, Sun ZW, Bone JR, Caldwell JA, et al. Set2 is a nucleosomal histone H3-selective methyltransferase that mediates transcriptional repression. Mol Cell Biol 2002; 22: 1298–306.
Forneris F, Battaglioli E, Mattevi A, Binda C . New roles of flavoproteins in molecular cell biology: Histone demethylase LSD1 and chromatin. FEBS J 2009; 276: 4304–12.
Sharma A, Heuck CJ, Fazzari MJ, Mehta J, Singhal S, Greally JM, et al. DNA methylation alterations in multiple myeloma as a model for epigenetic changes in cancer. Wiley Interdiscip Rev Syst Biol Med 2010; 2: 654–69.
Wang GG, Allis CD, Chi P . Chromatin remodeling and cancer, part I: covalent histone modifications. Trends Mol Med 2007; 13: 363–72.
Fodor BD, Kubicek S, Yonezawa M, O'Sullivan RJ, Sengupta R, Perez-Burgos L, et al. Jmjd2b antagonizes H3K9 trimethylation at pericentric heterochromatin in mammalian cells. Genes & Development 2006; 20: 1557–62.
Moreaux J, Hose D, Bonnefond A, Reme T, Robert N, Goldschmidt H, et al. MYEOV is a prognostic factor in multiple myeloma. Exp Hematology 2010; 38: 1189–98.
Lopez-Otero A, Ruiz-Delgado GJ, Hernandez-Arizpe A, Ruiz-Arguelles A, Ruiz-Arguelles GJ . The flow-cytometric DNA content of the plasma cells of patients with multiple myeloma is a prognostic factor: a single institution experience. Hematology 2010; 15: 378–81.
Feinberg AP, Ohlsson R, Henikoff S . The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006; 7: 21–33.
Ballestar E, Wolffe AP . Methyl-CpG-binding proteins —— Targeting specific gene repression. Eur J Biochem 2001; 268: 1–6.
Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J, et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 2007; 39: 232–6.
Shen JA, He CH . Isolation and purification of triptolide from the leaves of tripterygium wilfordii Hook F. Chin J Chem Engineering 2010; 18: 750–4.
Liu QY, Chen TY, Chen GY, Shu XL, Sun A, Ma PC, et al. Triptolide impairs dendritic cell migration by inhibiting CCR7 and COX-2 expression through PI3-K/Akt and NF-kappa B pathways. Mol Immunol 2007; 4: 2686–96.
Zhou B, Miao Z, Deng G, Ding J, Yang Y, Feng H, et al. Synthesis and biological evaluation of novel triptolide analogues for anticancer activity. Bioorg Med Chem Lett 2010; 20: 6217–21.
Jiang XH, Wong BCY, Lin MCM, Zhu GH, Kung HF, Jiang SH, et al. Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappa B activation in gastric cancer cells. Oncogene 2001; 20: 8009–18.
Lin J, Chen LY, Lin ZX, Zhao ML . The effect of triptolide on apoptosis of glioblastoma multiforme (GBM) cells. J Int Med Res 2007; 35: 637–43.
Lou YJ, Jie J, Wang YG . Triptolide inhibits transcription factor NF-kappaB and induces apoptosis of multiple myeloma cells. Leukemia Res 2005; 29: 99–105.
Zhou GX, Ding XL, Huang LF, Zhang H, Wu SB, Cheng JP, et al. Apoptosis of human pancreatic cancer cells induced by Triptolide. World J Gastroenterol 2008; 14: 1504–9.
Lou YJ, Jin J . Triptolide down-regulates bcr-abl expression and induces apoptosis in chronic myelogenous leukemia cells. Leukemia & Lymphoma 2004; 45: 373–6.
Phillips PA, Dudeja V, McCarroll JA, Borja-Cacho D, Dawra RK, Grizzle WE, et al. Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70. Cancer Res 2007; 67: 9407–16.
Liu YA, Zeng LL, Chen Y, Zhao F, Li R, Zhang C, et al. Triptolide inhibits cell growth and induces G0–G1 arrest by regulating P21wap1/cip1 and P27 kip1 in human multiple myeloma RPMI-8226 cells. Chin J Cancer Res 2010; 22: 141–7.
Tshuikina M, Jernberg-Wiklund H, Nilsson K, Oberg F . Epigenetic silencing of the interferon regulatory factor ICSBP/IRF8 in human multiple myeloma. Exp Hematol 2008; 36: 1673–81.
Yadav S, Singhal J, Singhal SS, Awasthi S . hSET1: A novel approach for colon cancer therapy. Biochem Pharmacol 2009; 77: 1635–41.
Shi YJ, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, et al. Histone demethylation mediated by the nuclear arnine oxidase homolog LSD1. Cell 2004; 119: 941–53.
Garcia-Bassets I, Kwon YS, Telese F, Prefontaine GG, Hutt KR, Cheng CS, et al. Histone methylation-dependent mechanisms impose ligand dependency for gene activation by nuclear receptors. Cell 2007; 128: 505–18.
Metzger E, Wissmann M, Yin N, Muller JM, Schneider R, Peters A, et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 2005; 437: 436–9.
Nottke AC, Beese-Sims SE, Pantalena LF, Reinke V, Shi Y, Colaiacovo MP . SPR-5 is a histone H3K4 demethylase with a role in meiotic double-strand break repair. Proc Natl Acad Sci U S A 2011; 108: 12805–10.
Kontaki H, Talianidis I . Lysine methylation regulates E2F1-induced cell death. Mol Cell 2010; 39: 152–60.
Koche RP, Smith ZD, Adli M, Gu H, Ku M, Gnirke A, et al. Reprogramming factor expression initiates widespread targeted chromatin remodeling. Cell Stem Cell 2011; 8: 96–105.
Huang J, Sengupta R, Espejo AB, Lee MG, Dorsey JA, Richter M, et al. p53 is regulated by the lysine demethylase LSD1. Nature 2007; 449: 105–8.
Keutgens A, Shostak K, Close P, Zhang X, Hennuy B, Aussems M, et al. The repressing function of the oncoprotein BCL-3 requires CtBP, while its polyubiquitination and degradation involve the E3 ligase TBLR1. Mol Cell Biol 2010; 30: 4006–21.
Huda A, Bowen NJ, Conley AB, Jordan IK . Epigenetic regulation of transposable element derived human gene promoters. Gene 2011; 475: 39–48.
Lim S, Janzer A, Becker A, Zimmer A, Schule R, Buettner R, et al. Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis 2010; 31: 512–20.
Black JC, Allen A, Van Rechem C, Forbes E, Longworth M, Tschöp K, et al. Conserved antagonism between JMJD2A/KDM4A and HP1γ during cell cycle progression. Mol Cell 2010; 40: 736–48.
Yang J, Jubb AM, Pike L, Buffa FM, Turley H, Baban D, et al. The Histone Demethylase JMJD2B Is Regulated by Estrogen Receptor alpha and Hypoxia, and Is a Key Mediator of Estrogen Induced Growth. Cancer Res 2010; 70: 6456–66.
Adamsen BL, Kravik KL, Clausen OPF, De Angelis PM . Apoptosis, cell cycle progression and gene expression in TP53-depleted HCT116 colon cancer cells in response to short-term 5-fluorouracil treatment. Int J Oncol 2007; 31: 1491–500.
Palomera-Sanchez Z, Zurita M . Open, repair and close again: chromatin dynamics and the response to UV-induced DNA damage. DNA Repair (Amst) 2011; 10: 119–25.